MedTrace Logo

Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy

NCT01623245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 294

Last updated 2019-08-14

No results posted yet for this study

Summary

Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture. Amyloidosis in transthyretin (TTR) are the most common hereditary amyloidosis but remain poorly studied at heart. This is serious and deadly. The prevalence of TTR amyloidosis is probably underestimated in hypertrophic cardiomyopathy (HCM) often of unknown etiology because of the lack of systematic implementation of myocardial biopsy because of their side effects.

Conditions

  • Cardiac Amyloidosis
  • Amyloidosis in Transthyretin (TTR)
  • Hypertrophic Cardiomyopathy (HCM)

Sponsors & Collaborators

  • Thibaud Damy

    lead OTHER

Principal Investigators

  • Thibaud DAMY · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623245 on ClinicalTrials.gov